Search by Drug Name or NDC

    NDC 00069-1031-30 Talzenna 0.1 mg/1 Details

    Talzenna 0.1 mg/1

    Talzenna is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is TALAZOPARIB TOSYLATE.

    Product Information

    NDC 00069-1031
    Product ID 0069-1031_207b4971-3031-45d7-b6a4-dfe66b37650c
    Associated GPIs
    GCN Sequence Number 084916
    GCN Sequence Number Description talazoparib tosylate CAPSULE 0.1 MG ORAL
    HIC3 V1Q
    HIC3 Description ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS
    GCN 54326
    HICL Sequence Number 045368
    HICL Sequence Number Description TALAZOPARIB TOSYLATE
    Brand/Generic Brand
    Proprietary Name Talzenna
    Proprietary Name Suffix n/a
    Non-Proprietary Name talazoparib
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form CAPSULE
    Route ORAL
    Active Ingredient Strength 0.1
    Active Ingredient Units mg/1
    Substance Name TALAZOPARIB TOSYLATE
    Labeler Name Pfizer Laboratories Div Pfizer Inc
    Pharmaceutical Class Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA211651
    Listing Certified Through 2024-12-31

    Package

    NDC 00069-1031-30 (00069103130)

    NDC Package Code 0069-1031-30
    Billing NDC 00069103130
    Package 1 BOTTLE in 1 CARTON (0069-1031-30) / 30 CAPSULE in 1 BOTTLE
    Marketing Start Date 2023-06-21
    NDC Exclude Flag N
    Pricing Information N/A